Title: | Characteristics of discharge prescriptions for patients with schizophrenia or major depressive disorder: Real-world evidence from the Effectiveness of Guidelines for Dissemination and Education (EGUIDE) psychiatric treatment project |
Authors: | Hashimoto, Naoki Browse this author |
Yasui-Furukori, Norio Browse this author |
Hasegawa, Naomi Browse this author |
Ishikawa, Shuhei Browse this author |
Numata, Shusuke Browse this author |
Hori, Hikaru Browse this author |
Iida, Hitoshi Browse this author |
Ichihashi, Kayo Browse this author |
Furihata, Ryuji Browse this author |
Murata, Atsunobu Browse this author |
Tsuboi, Takashi Browse this author |
Takeshima, Masahiro Browse this author |
Kyou, Yoshitaka Browse this author |
Komatsu, Hiroshi Browse this author |
Kubota, Chika Browse this author |
Ochi, Shinichiro Browse this author |
Takaesu, Yoshikazu Browse this author |
Usami, Masahide Browse this author |
Nagasawa, Tatsuya Browse this author |
Hishimoto, Akitoyo Browse this author |
Miura, Kenichiro Browse this author |
Matsumoto, Junya Browse this author |
Ohi, Kazutaka Browse this author |
Yamada, Hisashi Browse this author |
Inada, Ken Browse this author |
Watanabe, Koichiro Browse this author |
Shimoda, Kazutaka Browse this author |
Hashimoto, Ryota Browse this author |
Keywords: | Antipsychotics |
Antidepressants |
Monopharmacy |
Polypharmacy |
EGUIDE |
Issue Date: | Sep-2021 |
Publisher: | Elsevier |
Journal Title: | Asian Journal of Psychiatry |
Volume: | 63 |
Start Page: | 102744 |
Publisher DOI: | 10.1016/j.ajp.2021.102744 |
Abstract: | Background: Monopharmacy with antipsychotics and antidepressants is the first-line treatment for schizophrenia and major depressive disorder (MDD) in most clinical guidelines, while polypharmacy with psychotropic agents in the treatment of schizophrenia is common in clinical practice. There are no detailed data on the prescription patterns for inpatients with mental illness with reliable diagnoses made by treating psychiatrists. Methods: We gathered prescription data at discharge from 2177 patients with schizophrenia and 1238 patients with MDD from October 2016 to March 2018. Results: The patients with schizophrenia aged between 60 and 79 were prescribed lower doses of antipsychotics and hypnotics/anxiolytics than those aged between 40 and 59. There were significant differences between the prescription rate of antipsychotics in the patients with schizophrenia and that of antidepressants in the patients with MDD. The frequency of concomitant drugs such as anti-Parkinson drugs, anxiolytics/hypnotics and mood stabilizers in the subjects with schizophrenia prescribed antipsychotic polypharmacy was significantly higher than that with monotherapy. For the patients with schizophrenia, olanzapine, risperidone, aripiprazole, quetiapine, and blonanserin were the five most prescribed antipsychotics. For the patients with MDD, mirtazapine, duloxetine, escitalopram, trazodone and sertraline were the five most prescribed antidepressants. Conclusions: Our results showed the use of high doses of antipsychotics, high percentages of antipsychotic polypharmacy and concurrent use of hypnotics/anxiolytics in patients with schizophrenia. Notably, these data were collected before intensive instruction regarding the guidelines; therefore, we need to assess the change in the prescription pattern post guideline instruction. |
Type: | article |
URI: | http://hdl.handle.net/2115/82981 |
Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|